Drug Trial Radar · NCT00972738
Montelukast in Seasonal Allergic Rhinitis - Spring 2001 Study (0476-235)
Last checked: Nov 19, 2026Latest source record: Feb 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,214
Actual
Start
Apr 2001
Primary completion
Jul 2001
Study completion Jul 2001
Sponsor
- Lead sponsor
- Organon and CoIndustry
- Sponsor type
- Industry
- First posted
- Sep 7, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 15 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the treatment effect of montelukast versus placebo over a 2 week period in patients with seasonal allergic rhinitis. Loratadine is included in the study as an active comparator.
Conditions
- Seasonal Allergic Rhinitis
Interventions
montelukast sodiumDrug
Montelukast 10-mg tablet orally once daily at bedtime for 2 weeks.
Comparator: loratadineDrug
Loratadine 10-mg tablet orally once daily at bedtime for 2 weeks.
Comparator: PlaceboDrug
placebo tablet orally once daily at bedtime for 2 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline in Daytime Nasal Symptoms Score Over the 2-week Treatment PeriodTime frame: Baseline and over the 2-week treatment period
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.